Please login to the form below

Not currently logged in
Email:
Password:

Astellas Europe appoints Ken Jones as CEO

Ken Jones, chief operating officer of Astellas Pharma Europe, has been appointed president and CEO of the company

Ken Jones has been appointed president and CEO of Astellas Pharma Europe – the European subsidiary of Japan-based Astellas Pharma.

Jones, who leaves his role of current chief operating officer with the company, takes over from Masao Yoshida who has been appointed as president and CEO of Astellas' US division.

"I am delighted and honoured to be taking on this new role and I look forward to building on Astellas Pharma Europe's considerable achievements," said Jones. "In spite of the tough market conditions which the industry is facing, we're in a strong position and have clear strategies for growth through expanding and developing our core franchises."

These strategies include expanding the company's efforts into pain management, anti-infectives and oncology while maintaining a leading presence in transplantation and urology.

In line with these plans, Astellas has entered several partnerships recently, including a deal with Optimer Pharmaceuticals involving the development and commercialisation in Europe of clostridium difficile treatment, fidaxomicin. Astellas has also agreed a partnership deal with AVEO Pharmaceuticals to develop investigational cancer treatment, tivozanib.

Jones joined Yamanouchi as vice president, European marketing, in 2003. Yamanouchi then merged with Fujisawa to form Astellas in 2005, with Jones being promoted to senior vice president, sales, marketing and medical.

Prior to his work with Astellas, he spent 16 years with Allergan working in Europe, the US and Japan.

11th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...

Infographics